The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -19,272 | -20,175 | -20,275 | -50,147 |
| Depreciation and amortization | 1,763 | 1,827 | 1,864 | 4,745 |
| Amortization (accretion) of premium (discount) on marketable securities | 0 | 0 | 111 | 300 |
| Stock-based compensation | 2,196 | 2,745 | 2,934 | 7,367 |
| Non-cash operating lease expense | 654 | 640 | 625 | 1,208 |
| Other | -8 | -130 | -63 | -230 |
| Accounts receivable | 10,627 | - | - | - |
| Prepaid expenses and other current assets | 9 | 167 | 774 | -1,488 |
| Other noncurrent assets | -461 | 2 | -65 | -508 |
| Accounts payable | -1,460 | 531 | -447 | -1,514 |
| Accrued and other current liabilities | -2,637 | 1,126 | 918 | -1,512 |
| Contract liabilities | 10,402 | - | - | - |
| Operating lease liabilities | -713 | -697 | -683 | -1,398 |
| Other noncurrent liabilities | - | 102 | - | - |
| Net cash used in operating activities | -19,234 | -13,940 | -15,599 | -38,725 |
| Purchases of property and equipment | 11 | 67 | 26 | 525 |
| Purchases of marketable securities | - | 0 | 0 | - |
| Proceeds from sales of marketable securities | 0 | 0 | 0 | 10,958 |
| Proceeds from maturities of marketable securities | 0 | 0 | 8,886 | 36,857 |
| Other | - | 0 | 0 | 0 |
| Net cash (used) provided by investing activities | -11 | -67 | 8,860 | 47,290 |
| Proceeds from issuance of equity, net of issuance costs-Follow On Offering | 0 | 56,264 | 0 | 48,801 |
| Proceeds from exercise of stock options and employee stock purchase plan | - | 45 | 24 | 70 |
| Proceeds from exercise of warrants | - | 1,933 | 356 | - |
| Proceeds from exercises of pre-funded warrants | - | 0 | 0 | - |
| Proceeds from issuance of equity, net of issuance costs-At The Market Offering | 0 | 0 | 0 | 912 |
| Payment of accrued offering costs | 415 | - | - | - |
| Net cash (used) provided by financing activities | -415 | 58,242 | 380 | 49,783 |
| Net change in cash, cash equivalents and restricted cash | -19,660 | 44,235 | -6,359 | 58,348 |
| Cash and cash equivalents and restricted cash at beginning of period | 100,966 | 56,731 | 4,742 | - |
| Cash and cash equivalents and restricted cash at end of period | 81,306 | 100,966 | 56,731 | - |
Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc. (TNYA)